BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21651836)

  • 1. Factors that determine whether a patient receives completion axillary lymph node dissection after a positive sentinel lymph node biopsy for breast cancer in British Columbia.
    Aslani N; Swanson T; Kennecke H; Woods R; Davis N
    Can J Surg; 2011 Aug; 54(4):237-42. PubMed ID: 21651836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
    Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
    Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease recurrence in sentinel node-positive breast cancer patients forgoing axillary lymph node dissection.
    Cyr A; Gao F; Gillanders WE; Aft RL; Eberlein TJ; Margenthaler JA
    Ann Surg Oncol; 2012 Oct; 19(10):3185-91. PubMed ID: 22890591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Population-Based Study of the Effects of a Regional Guideline for Completion Axillary Lymph Node Dissection on Axillary Surgery in Patients with Breast Cancer.
    Tsao MW; Cornacchi SD; Hodgson N; Simunovic M; Thabane L; Cheng J; O'Brien MA; Strang B; Mukherjee SD; Lovrics PJ
    Ann Surg Oncol; 2016 Oct; 23(10):3354-64. PubMed ID: 27342830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporating Lymphovenous Anastomosis in Clinically Node-Positive Women Receiving Neoadjuvant Chemotherapy: A Shared Decision-Making Model and Nuanced Approached to the Axilla.
    Lustig DB; Temple-Oberle C; Bouchard-Fortier A; Quan ML
    Curr Oncol; 2023 Apr; 30(4):4041-4051. PubMed ID: 37185419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subsequent axillary surgery after sentinel lymph node biopsy: results from the BreastSurgANZ Quality Audit 2006-2010.
    Chong C; Walters D; de Silva P; Taylor C; Spillane A; Kollias J; Pyke C; Campbell I; Maddern G
    Breast; 2013 Dec; 22(6):1215-9. PubMed ID: 24157405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axillary recurrence after a tumor-positive sentinel lymph node biopsy without axillary treatment: a review of the literature.
    Francissen CM; Dings PJ; van Dalen T; Strobbe LJ; van Laarhoven HW; de Wilt JH
    Ann Surg Oncol; 2012 Dec; 19(13):4140-9. PubMed ID: 22890590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study.
    Hennigs A; Riedel F; Feißt M; Köpke M; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Heil J
    Ann Surg Oncol; 2019 Aug; 26(8):2435-2443. PubMed ID: 31049766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.
    Stafford AP; Hoskin TL; Day CN; Sanders SB; Boughey JC
    Ann Surg Oncol; 2022 Aug; 29(8):4740-4749. PubMed ID: 35451727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer?
    Farley C; Bassett R; Meric-Bernstam F; Bedrosian I; Caudle A; DeSnyder S; Hunt K; Kuerer H; Singh P; Sun S; Tamirisa N; Teshome M; Hwang RF
    Ann Surg Oncol; 2023 Dec; 30(13):8327-8334. PubMed ID: 37670121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sentinel lymph node biopsy in multicentric breast cancer: five-year results in a large series from a single institution.
    Gentilini O; Veronesi P; Botteri E; Soggiu F; Trifirò G; Lissidini G; Galimberti V; Musmeci S; Raviele PR; Toesca A; Ratini S; Del Castillo A; Colleoni M; Talakhadze N; Rotmensz N; Viale G; Veronesi U; Luini A
    Ann Surg Oncol; 2011 Oct; 18(10):2879-84. PubMed ID: 21479691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Locoregional Management of the Axilla in Mastectomy Patients with One or Two Positive Sentinel Nodes: The Role of Intraoperative Pathology.
    Davis J; Boughey JC; Hoskin TL; Day CN; Cheville JC; Piltin MA; Hieken TJ
    Clin Breast Cancer; 2021 Oct; 21(5):458-465. PubMed ID: 33839043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of completion axillary lymph node dissection in patients with positive sentinel lymph nodes.
    Karam AK; Hsu M; Patil S; Stempel M; Traina TA; Ho AY; Cody HS; Port ER; Morrow M; Gemignani ML
    Ann Surg Oncol; 2009 Jul; 16(7):1952-8. PubMed ID: 19381724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of non-sentinel lymph node metastasis in breast cancer patients.
    Goyal A; Douglas-Jones A; Newcombe RG; Mansel RE;
    Eur J Cancer; 2004 Jul; 40(11):1731-7. PubMed ID: 15251163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The exportability of the ACOSOG Z0011 criteria for omitting axillary lymph node dissection after positive sentinel lymph node biopsy findings: a multicenter study.
    Delpech Y; Bricou A; Lousquy R; Hudry D; Jankowski C; Willecocq C; Thoury A; Loustalot C; Coutant C; Barranger E
    Ann Surg Oncol; 2013 Aug; 20(8):2556-61. PubMed ID: 23456432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When is a completion axillary lymph node dissection necessary in the presence of a positive sentinel lymph node?
    Suyoi A; Bains SK; Kothari A; Douek M; Agbaje O; Hamed H; Fentiman I; Pinder S; Purushotham AD
    Eur J Cancer; 2014 Mar; 50(4):690-7. PubMed ID: 24331957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival outcomes in node-negative breast cancer patients evaluated with complete axillary node dissection versus sentinel lymph node biopsy.
    Cox C; White L; Allred N; Meyers M; Dickson D; Dupont E; Cantor A; Ly Q; Dessureault S; King J; Nicosia S; Vrcel V; Diaz N
    Ann Surg Oncol; 2006 May; 13(5):708-11. PubMed ID: 16538416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Influencing Non-sentinel Lymph Node Involvement in Patients with Positive Sentinel Lymph Node(s) After Neoadjuvant Chemotherapy for Breast Cancer.
    Sanders SB; Hoskin TL; Stafford AP; Boughey JC
    Ann Surg Oncol; 2022 Nov; 29(12):7769-7778. PubMed ID: 35834142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sentinel node positive breast cancer patients who do not undergo axillary dissection: are they different?
    Zakaria S; Pantvaidya G; Reynolds CA; Grant CS; Sterioff S; Donohue JH; Farley DR; Hoskin TL; Degnim AC
    Surgery; 2008 May; 143(5):641-7. PubMed ID: 18436012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.